http://www.arthritistreatmentcenter.com Why do some people treated for psoriatic arthritis stop responding to their treatment? Find out next. Study Confirms High Prevalence of ADA in Adalimumab-Treated Psoriasis Dr. Graeme M. Lipper, writing in Medscape described a recent study that might shed light on why some treatments for psoriatic arthritis may fail over time. Menting, Lumig, DeVries and colleagues published the results of a recent study entitled Extent and Consequences of Antibody Formation Against Adalimumab in Patients With Psoriasis: One-Year Follow-up Adalimumab, a humanized monoclonal antibody (IgG1) that binds to and inactivates the proinflammatory cytokine tumor necrosis factor alpha, is a highly effective treatment for moderate to severe psoriatic arthritis. Unfortunately, this drug may induce antidrug antibodies (ADAs) in almost one half of patients taking adalimumab long-term, and prior studies show that ADAs contribute to disease relapse and waning therapeutic response to adalimumab and other biologic therapies. In their study they found that 49 % of patients developed ADAs, with the vast majority (90%) forming antibody titers within the first 24 weeks of therapy. Comment: Interesting and answers a lot of questions about failing therapy. http://youtu.be/waybYv26phU

• published: 05 May 2014
• views: 8